Our genetic screen fulfilled two important requirements: it utilized (i) an age-dependent model of [A53T]α-Synuclein toxicity, and (ii) an endpoint that is relevant to PD, this being the loss of DA. This evidence concerns the gene SNCA and Parkinson disease.